Temporary Imports for Trade Shows, Demonstrations, and Evaluation

A device does not fall outside FDA jurisdiction merely because it is not being sold—or because it has not yet been cleared. If the product is represented or intended for a medical purpose, it may still be a medical device, and FDA may review applicable requirements when it is imported or offered for import into the United States. In fact, the absence of clearance, approval, or an applicable exemption is often the reason the proposed import requires closer planning.

The intended activity matters. A nonfunctional model kept behind a trade-show barrier presents a different regulatory profile from an operational device demonstrated on a person, loaned to a hospital, or supplied to clinicians for evaluation. “Not for sale,” “sample,” and “no commercial value” describe the commercial arrangement; they do not establish an FDA exemption.

Exhibition Controls May Still Apply

FDA procedures contemplate that a noncompliant regulated article may sometimes be admitted solely for exhibition, subject to controls such as prominent placarding, prevention of unauthorized use or distribution, and re-exportation or destruction after the event. Although published guidance may suggest contacting the responsible FDA office in advance, that is often impractical in real-world import operations. FDA personnel processing very large shipment volumes may be unable or unwilling to provide advance shipment-specific clearance.

Evaluation Must Be Carefully Defined

“Evaluation” also requires careful definition. Bench testing, engineering review, usability work, and display-only demonstrations may be distinguishable from clinical investigation. However, when a device is used on a person or the activity is designed to assess safety or effectiveness, investigational-device requirements may apply. These may include an Investigational Device Exemption (IDE), appropriate investigational labeling, informed consent, and review by an Institutional Review Board (IRB)—the U.S. term for an independent ethics committee. Calling the activity a demonstration does not change what is actually being done.

Customs Treatment Is a Separate Analysis

Customs treatment is a separate analysis. A Temporary Importation Under Bond or an Admission Temporaire/Temporary Admission (ATA) Carnet may permit qualifying goods to enter temporarily without ordinary duty payment, but neither mechanism authorizes an otherwise impermissible FDA import. Classification, valuation, entry documentation, custody, and timely re-exportation or other authorized disposition must still be managed.

The safest approach is to define the device, quantity, location, users, activities, duration, custody, and final disposition before shipment. Otherwise, a courier package described simply as a “trade-show sample” may arrive without the information or regulatory basis needed for FDA and Customs and Border Protection release.

MDD Options can use its hybrid import and distribution infrastructure as the controlled U.S. receiving, custody, and disposition point for temporary devices. This can include storage before an event, secure holding between successive trade shows or demonstrations, and continued storage while FDA clearance is imminent and the company prepares for commercial launch. MDD Options can also coordinate entry data, broker instructions, transport, event delivery, return logistics, re-exportation, or destruction, with targeted consulting for unusual exhibition, demonstration, evaluation, or investigational scenarios.